US EditionPublished • loading... • Updated
Shine On: DISCO Licenses Novel AND-Gated Cancer Target to Amgen
Summary by Inside Precision Medicine
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Shine On: DISCO Licenses Novel AND-Gated Cancer Target to Amgen
Oncology, an industry awash with ever-more sophisticated drugs, has a target problem. Industry reports from 2025 reveal that oncology R&D is highly concentrated, with ~25% of drug-target pairs targeting 38 targets and over 80% of cancer targets facing multiple competing clinical candidates. In other words, oncology R&D primarily concentrates on a tiny slice of the (theoretically) druggable world. This extremely limited target set is rooted in a …
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
